<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05619055</url>
  </required_header>
  <id_info>
    <org_study_id>YXLL-KY-2022(018)</org_study_id>
    <nct_id>NCT05619055</nct_id>
  </id_info>
  <brief_title>The Intestinal Dysbacteriosis in the Pathogenesis of Necrotizing Enterocolitis</brief_title>
  <official_title>The Role and Mechanism of Intestinal Dysbacteriosis Impairing the Intestinal Mucosal Barrier in the Pathogenesis of Necrotizing Enterocolitis in Premature Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zuohui Zhao</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qianfoshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study Description&#xD;
&#xD;
      The goal of this observational study is to detect intestinal flora and the metabolic products&#xD;
      in premature infants diagnosed as necrotizing enterocolitis. The main questions it aims to&#xD;
      answer are:&#xD;
&#xD;
        -  1. Whether there is intestinal flora in the stool of premature infants.&#xD;
&#xD;
        -  2. Are there dysregulated intestinal flora and their metabolic products in premature&#xD;
           infants diagnosed as necrotizing enterocolitis.&#xD;
&#xD;
        -  3. The detailed role and underlying mechanism of the intestinal dysbacteriosis and the&#xD;
           metabolic products in premature infants diagnosed as necrotizing enterocolitis.&#xD;
&#xD;
      Participants, premature infants diagnosed as necrotizing enterocolitis (NEC group), will be&#xD;
      asked to collect stool (usually 2 times) for intestinal flora analysis.&#xD;
&#xD;
      If there is a comparison group: Researchers will compare premature infants without&#xD;
      necrotizing enterocolitis (control group) to see if their intestinal flora and the metabolic&#xD;
      products also changed as their NEC counterparts.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When the patients is hospitalized in neonatology, we screen the premature infants according&#xD;
      to the selection criteria and exclusion criteria. After sighed the informed consent, they are&#xD;
      classified into two groups: premature infants diagnosed as necrotizing enterocolitis (NEC&#xD;
      group) and premature infants without necrotizing enterocolitis (control group). Their stool&#xD;
      and blood (usually 2 times ) are collected for intestinal flora and FABP (including L-FABP&#xD;
      and I-FABP) analysis, respectively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 5, 2022</start_date>
  <completion_date type="Anticipated">March 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>intestinal flora</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>the intestinal flora in the stool using 16S ribosomal RNA(rRNA) gene sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>short-chain fatty acids</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>short-chain fatty acids, the metabolic products of intestinal flora, in the stool using 16S rRNA gene sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>neurotransmitters</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>neurotransmitters, the metabolic products of intestinal flora, in the stool using 16S rRNA gene sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lipopolysaccharide</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>lipopolysaccharide, a metabolic product of intestinal flora, in the stool using 16S rRNA gene sequencing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>L-FABP</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>L-FABP, the injury marker of intestinal mucosa, in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>I-FABP</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>I-FABP, the injury marker of intestinal mucosa, in the blood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>hospital stay</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>one vital clinical outcome of the premature infants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>X-ray</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>one important clinical imaging data of the premature infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete blood count</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>complete blood count, one vital laboratory test of the premature infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>c-reactive protein</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>c-reactive protein, one vital laboratory test of the premature infants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procalcitonin</measure>
    <time_frame>up to 4 weeks</time_frame>
    <description>procalcitonin, one vital laboratory test of the premature infants</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Necrotizing Enterocolitis of Newborn</condition>
  <arm_group>
    <arm_group_label>neonate with necrotizing enterocolitis</arm_group_label>
    <description>premature infants diagnosed as necrotizing enterocolitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neonate without necrotizing enterocolitis</arm_group_label>
    <description>premature infants without necrotizing enterocolitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine treatment</intervention_name>
    <description>Antibiotics, intravenous fluids and symptomatic supportive treatment.</description>
    <arm_group_label>neonate with necrotizing enterocolitis</arm_group_label>
    <arm_group_label>neonate without necrotizing enterocolitis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized children in Neonatology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  clinical diagnosis of Necrotizing Enterocolitis,&#xD;
&#xD;
          -  gestational age &lt;37 weeks,&#xD;
&#xD;
          -  body weight 1,000-2,500 g,&#xD;
&#xD;
          -  postnatal Apgar score â‰¥7,&#xD;
&#xD;
          -  initial oral feeding tolerance.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  serious hereditary or other serious diseases, such as heart, lung and abdominal&#xD;
             malformations ,&#xD;
&#xD;
          -  early or late onset septicemia,&#xD;
&#xD;
          -  early use of antibiotics in the newborn,&#xD;
&#xD;
          -  serious adverse reactions caused by probiotics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Days</minimum_age>
    <maximum_age>2 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zuohui Zhao, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital of Shandong First Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zuohui Zhao, Dr</last_name>
    <phone>0086-531-89268509</phone>
    <email>zhaozuohui@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiahui Li, Dr</last_name>
    <phone>0086-531-89268508</phone>
    <email>2149@sdhospital.com.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Shandong First Medical University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenjiao Jiao</last_name>
      <phone>0086-531-89269891</phone>
      <email>qykyc309@163.com</email>
    </contact>
    <investigator>
      <last_name>Zuohui Zhao, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 2, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Qianfoshan Hospital</investigator_affiliation>
    <investigator_full_name>Zuohui Zhao</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Necrotizing Enterocolitis</keyword>
  <keyword>intestinal flora</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The clinical data to collect for individual participant is not public for the time being.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

